Fate Therapeutics, Inc. (FATE) Stock

Fate Therapeutics, Inc. (FATE) is a Healthcare stock trading at $2.07 (as of 2026-06-18), with a market capitalization of $314.13M and a trailing P/E of -1.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies, including NK- and T-cell approaches, for cancer and immune disorders. Its pipeline includes multiple product candidates targeting conditions such as acute myeloid leukemia, B-cell lymphoma, chronic lymphocytic leukemia, multiple myeloma, and other hematologic malignancies and solid tumors.

Valuation — source: SEC EDGAR (first-party)
Price	$2.07
Market Cap	$314.13M
P/E Ratio	-1.9
EV / EBITDA	-1.6
Price / Book	1.36
Price / Sales	38.57
DCF Value (model)	$-16.00
DCF Upside vs Price	-872.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$6.65M
Net Margin	-2051.1%
Return on Equity	-72.3%
Current Ratio	5.85
Revenue Growth (YoY)	-51.2%
EPS Growth (YoY)	-29.9%
FCF Growth (YoY)	-9.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	-6.30 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.9
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-109.2%
vs Industry	-111.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Redmile Group, LLC ($15.45M)
Institutional Holders Tracked	10
Congressional Trades (recent)	1

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Bahram Valamehr
Employees	181
Country	US
IPO Date	2013-10-01

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.